APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peripheral Vasodilator Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Peripheral Vasodilator Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025192 pages

Choose your research edition.

Industry ResearchPeripheral Vasodilator Drugs Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Peripheral Vasodilator Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Peripheral Vasodilator Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peripheral Vasodilator Drugs Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Peripheral Vasodilator Drugs Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Peripheral Vasodilator Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Peripheral Vasodilator Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peripheral Vasodilator Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peripheral Vasodilator Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Peripheral Vasodilator Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peripheral Vasodilator Drugs include Endovastec, Aotecar Medical-B, Tibet Cheezheng Tibetan Medicine Co., Ltd, Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Pfizer, Inc., GSK plc and Bayer AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peripheral Vasodilator Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peripheral Vasodilator Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peripheral Vasodilator Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peripheral Vasodilator Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Peripheral Vasodilator Drugs Segment by Company

Endovastec

Aotecar Medical-B

Tibet Cheezheng Tibetan Medicine Co., Ltd

Teva Pharmaceutical Industries Ltd.

Sanofi

Novartis AG

Pfizer, Inc.

GSK plc

Bayer AG

Bat Medical

AstraZeneca

Viatris, Inc.

Sun Pharmaceutical Industries Ltd.

Merck & Co., Inc.

Lupin

Bristol-Myers Squibb Company

Boehringer Ingelheim International GmbH

Abbott Laboratories

Peripheral Vasodilator Drugs Segment by Type

Alpha-adrenergic Blockers

Calcium Channel Blockers

Potassium Channel Activators

Others

Peripheral Vasodilator Drugs Segment by Application

Hospital

Retail Pharmacies

Others

Peripheral Vasodilator Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peripheral Vasodilator Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peripheral Vasodilator Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peripheral Vasodilator Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peripheral Vasodilator Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peripheral Vasodilator Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Peripheral Vasodilator Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Peripheral Vasodilator Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Peripheral Vasodilator Drugs Industry Trends Table 2. Peripheral Vasodilator Drugs Industry Drivers Table 3. Peripheral Vasodilator Drugs Industry Opportunities and Challenges Table 4. Peripheral Vasodilator Drugs Industry Restraints Table 5. Global Peripheral Vasodilator Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Peripheral Vasodilator Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Peripheral Vasodilator Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Peripheral Vasodilator Drugs Sales Market Share by Manufacturers Table 9. Global Peripheral Vasodilator Drugs Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Peripheral Vasodilator Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Peripheral Vasodilator Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Peripheral Vasodilator Drugs Manufacturers, Product Type & Application Table 13. Global Peripheral Vasodilator Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Peripheral Vasodilator Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Alpha-adrenergic Blockers Table 17. Major Manufacturers of Calcium Channel Blockers Table 18. Major Manufacturers of Potassium Channel Activators Table 19. Major Manufacturers of Others Table 20. Global Peripheral Vasodilator Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Peripheral Vasodilator Drugs Sales by Type (2021-2026) & (k units) Table 22. Global Peripheral Vasodilator Drugs Sales by Type (2027-2032) & (k units) Table 23. Global Peripheral Vasodilator Drugs Sales Market Share by Type (2021-2026) Table 24. Global Peripheral Vasodilator Drugs Sales Market Share by Type (2027-2032) Table 25. Global Peripheral Vasodilator Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Peripheral Vasodilator Drugs Revenue by Type (2021-2026) & (k units) Table 27. Global Peripheral Vasodilator Drugs Revenue by Type (2027-2032) & (k units) Table 28. Global Peripheral Vasodilator Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Peripheral Vasodilator Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Retail Pharmacies Table 32. Major Manufacturers of Others Table 33. Global Peripheral Vasodilator Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Peripheral Vasodilator Drugs Sales by Application (2021-2026) & (k units) Table 35. Global Peripheral Vasodilator Drugs Sales by Application (2027-2032) & (k units) Table 36. Global Peripheral Vasodilator Drugs Sales Market Share by Application (2021-2026) Table 37. Global Peripheral Vasodilator Drugs Sales Market Share by Application (2027-2032) Table 38. Global Peripheral Vasodilator Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Peripheral Vasodilator Drugs Revenue by Application (2021-2026) & (k units) Table 40. Global Peripheral Vasodilator Drugs Revenue by Application (2027-2032) & (k units) Table 41. Global Peripheral Vasodilator Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Peripheral Vasodilator Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Peripheral Vasodilator Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Peripheral Vasodilator Drugs Sales by Region (2021-2026) & (k units) Table 45. Global Peripheral Vasodilator Drugs Sales Market Share by Region (2021-2026) Table 46. Global Peripheral Vasodilator Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Peripheral Vasodilator Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Peripheral Vasodilator Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Peripheral Vasodilator Drugs Sales by Country (2021-2026) & (k units) Table 50. North America Peripheral Vasodilator Drugs Sales by Country (2027-2032) & (k units) Table 51. Europe Peripheral Vasodilator Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Peripheral Vasodilator Drugs Sales by Country (2021-2026) & (k units) Table 53. Europe Peripheral Vasodilator Drugs Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Peripheral Vasodilator Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Peripheral Vasodilator Drugs Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Peripheral Vasodilator Drugs Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Peripheral Vasodilator Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Peripheral Vasodilator Drugs Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Peripheral Vasodilator Drugs Sales by Country (2027-2032) & (k units) Table 60. Global Peripheral Vasodilator Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Peripheral Vasodilator Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Peripheral Vasodilator Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Peripheral Vasodilator Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Peripheral Vasodilator Drugs Revenue Market Share by Region (2027-2032) Table 65. Endovastec Company Information Table 66. Endovastec Business Overview Table 67. Endovastec Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Endovastec Peripheral Vasodilator Drugs Product Portfolio Table 69. Endovastec Recent Development Table 70. Aotecar Medical-B Company Information Table 71. Aotecar Medical-B Business Overview Table 72. Aotecar Medical-B Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Aotecar Medical-B Peripheral Vasodilator Drugs Product Portfolio Table 74. Aotecar Medical-B Recent Development Table 75. Tibet Cheezheng Tibetan Medicine Co., Ltd Company Information Table 76. Tibet Cheezheng Tibetan Medicine Co., Ltd Business Overview Table 77. Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Product Portfolio Table 79. Tibet Cheezheng Tibetan Medicine Co., Ltd Recent Development Table 80. Teva Pharmaceutical Industries Ltd. Company Information Table 81. Teva Pharmaceutical Industries Ltd. Business Overview Table 82. Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio Table 84. Teva Pharmaceutical Industries Ltd. Recent Development Table 85. Sanofi Company Information Table 86. Sanofi Business Overview Table 87. Sanofi Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sanofi Peripheral Vasodilator Drugs Product Portfolio Table 89. Sanofi Recent Development Table 90. Novartis AG Company Information Table 91. Novartis AG Business Overview Table 92. Novartis AG Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Novartis AG Peripheral Vasodilator Drugs Product Portfolio Table 94. Novartis AG Recent Development Table 95. Pfizer, Inc. Company Information Table 96. Pfizer, Inc. Business Overview Table 97. Pfizer, Inc. Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Pfizer, Inc. Peripheral Vasodilator Drugs Product Portfolio Table 99. Pfizer, Inc. Recent Development Table 100. GSK plc Company Information Table 101. GSK plc Business Overview Table 102. GSK plc Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. GSK plc Peripheral Vasodilator Drugs Product Portfolio Table 104. GSK plc Recent Development Table 105. Bayer AG Company Information Table 106. Bayer AG Business Overview Table 107. Bayer AG Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Bayer AG Peripheral Vasodilator Drugs Product Portfolio Table 109. Bayer AG Recent Development Table 110. Bat Medical Company Information Table 111. Bat Medical Business Overview Table 112. Bat Medical Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Bat Medical Peripheral Vasodilator Drugs Product Portfolio Table 114. Bat Medical Recent Development Table 115. AstraZeneca Company Information Table 116. AstraZeneca Business Overview Table 117. AstraZeneca Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. AstraZeneca Peripheral Vasodilator Drugs Product Portfolio Table 119. AstraZeneca Recent Development Table 120. Viatris, Inc. Company Information Table 121. Viatris, Inc. Business Overview Table 122. Viatris, Inc. Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Viatris, Inc. Peripheral Vasodilator Drugs Product Portfolio Table 124. Viatris, Inc. Recent Development Table 125. Sun Pharmaceutical Industries Ltd. Company Information Table 126. Sun Pharmaceutical Industries Ltd. Business Overview Table 127. Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio Table 129. Sun Pharmaceutical Industries Ltd. Recent Development Table 130. Merck & Co., Inc. Company Information Table 131. Merck & Co., Inc. Business Overview Table 132. Merck & Co., Inc. Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Merck & Co., Inc. Peripheral Vasodilator Drugs Product Portfolio Table 134. Merck & Co., Inc. Recent Development Table 135. Lupin Company Information Table 136. Lupin Business Overview Table 137. Lupin Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Lupin Peripheral Vasodilator Drugs Product Portfolio Table 139. Lupin Recent Development Table 140. Bristol-Myers Squibb Company Company Information Table 141. Bristol-Myers Squibb Company Business Overview Table 142. Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Product Portfolio Table 144. Bristol-Myers Squibb Company Recent Development Table 145. Boehringer Ingelheim International GmbH Company Information Table 146. Boehringer Ingelheim International GmbH Business Overview Table 147. Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Product Portfolio Table 149. Boehringer Ingelheim International GmbH Recent Development Table 150. Abbott Laboratories Company Information Table 151. Abbott Laboratories Business Overview Table 152. Abbott Laboratories Peripheral Vasodilator Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Abbott Laboratories Peripheral Vasodilator Drugs Product Portfolio Table 154. Abbott Laboratories Recent Development Table 155. Key Raw Materials Table 156. Raw Materials Key Suppliers Table 157. Peripheral Vasodilator Drugs Distributors List Table 158. Peripheral Vasodilator Drugs Customers List Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Peripheral Vasodilator Drugs Product Image Figure 2. Global Peripheral Vasodilator Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peripheral Vasodilator Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Peripheral Vasodilator Drugs Sales (2021-2032) & (k units) Figure 5. Global Peripheral Vasodilator Drugs Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Peripheral Vasodilator Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Alpha-adrenergic Blockers Image Figure 9. Calcium Channel Blockers Image Figure 10. Potassium Channel Activators Image Figure 11. Others Image Figure 12. Global Peripheral Vasodilator Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Peripheral Vasodilator Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Peripheral Vasodilator Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Peripheral Vasodilator Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Peripheral Vasodilator Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Peripheral Vasodilator Drugs Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Retail Pharmacies Image Figure 20. Others Image Figure 21. Global Peripheral Vasodilator Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Peripheral Vasodilator Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Peripheral Vasodilator Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Peripheral Vasodilator Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Peripheral Vasodilator Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Peripheral Vasodilator Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Peripheral Vasodilator Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Peripheral Vasodilator Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Peripheral Vasodilator Drugs Sales Market Share by Country (2021-2032) Figure 41. China Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Peripheral Vasodilator Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Peripheral Vasodilator Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Peripheral Vasodilator Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Peripheral Vasodilator Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Peripheral Vasodilator Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Peripheral Vasodilator Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Peripheral Vasodilator Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Peripheral Vasodilator Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Peripheral Vasodilator Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Peripheral Vasodilator Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Peripheral Vasodilator Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Peripheral Vasodilator Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Peripheral Vasodilator Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Peripheral Vasodilator Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Alpha-adrenergic Blockers
  • Calcium Channel Blockers
  • Potassium Channel Activators
  • Others
Applications
  • Hospital
  • Retail Pharmacies
  • Others
Companies covered
  • Endovastec
  • Aotecar Medical-B
  • Tibet Cheezheng Tibetan Medicine Co., Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Pfizer, Inc.
  • GSK plc
  • Bayer AG
  • Bat Medical
  • AstraZeneca
  • Viatris, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Lupin
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peripheral Vasodilator Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peripheral Vasodilator Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Peripheral Vasodilator Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Peripheral Vasodilator Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Peripheral Vasodilator Drugs Market Dynamics
  1. 2.1 Peripheral Vasodilator Drugs Industry Trends
  2. 2.2 Peripheral Vasodilator Drugs Industry Drivers
  3. 2.3 Peripheral Vasodilator Drugs Industry Opportunities and Challenges
  4. 2.4 Peripheral Vasodilator Drugs Industry Restraints
3 Peripheral Vasodilator Drugs Market by Manufacturers
  1. 3.1 Global Peripheral Vasodilator Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Peripheral Vasodilator Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Peripheral Vasodilator Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Peripheral Vasodilator Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peripheral Vasodilator Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Peripheral Vasodilator Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Peripheral Vasodilator Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peripheral Vasodilator Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peripheral Vasodilator Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peripheral Vasodilator Drugs Tier 1, Tier 2, and Tier 3
4 Peripheral Vasodilator Drugs Market by Type
  1. 4.1 Peripheral Vasodilator Drugs Type Introduction
  2. 4.1.1 Alpha-adrenergic Blockers
  3. 4.1.2 Calcium Channel Blockers
  4. 4.1.3 Potassium Channel Activators
  5. 4.1.4 Others
  6. 4.2 Global Peripheral Vasodilator Drugs Sales by Type
  7. 4.2.1 Global Peripheral Vasodilator Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Peripheral Vasodilator Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Peripheral Vasodilator Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Peripheral Vasodilator Drugs Revenue by Type
  11. 4.3.1 Global Peripheral Vasodilator Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Peripheral Vasodilator Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Peripheral Vasodilator Drugs Revenue Market Share by Type (2021-2032)
5 Peripheral Vasodilator Drugs Market by Application
  1. 5.1 Peripheral Vasodilator Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Others
  5. 5.2 Global Peripheral Vasodilator Drugs Sales by Application
  6. 5.2.1 Global Peripheral Vasodilator Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peripheral Vasodilator Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Peripheral Vasodilator Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Peripheral Vasodilator Drugs Revenue by Application
  10. 5.3.1 Global Peripheral Vasodilator Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peripheral Vasodilator Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Peripheral Vasodilator Drugs Revenue Market Share by Application (2021-2032)
6 Global Peripheral Vasodilator Drugs Sales by Region
  1. 6.1 Global Peripheral Vasodilator Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peripheral Vasodilator Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Peripheral Vasodilator Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Peripheral Vasodilator Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peripheral Vasodilator Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Peripheral Vasodilator Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Peripheral Vasodilator Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Peripheral Vasodilator Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Peripheral Vasodilator Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Peripheral Vasodilator Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Peripheral Vasodilator Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Peripheral Vasodilator Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Peripheral Vasodilator Drugs Revenue by Region
  1. 7.1 Global Peripheral Vasodilator Drugs Revenue by Region
  2. 7.1.1 Global Peripheral Vasodilator Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Peripheral Vasodilator Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Peripheral Vasodilator Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Peripheral Vasodilator Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Peripheral Vasodilator Drugs Revenue (2021-2032)
  8. 7.2.2 North America Peripheral Vasodilator Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Peripheral Vasodilator Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Peripheral Vasodilator Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Peripheral Vasodilator Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Peripheral Vasodilator Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Peripheral Vasodilator Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Peripheral Vasodilator Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Endovastec
  2. 8.1.1 Endovastec Company Information
  3. 8.1.2 Endovastec Business Overview
  4. 8.1.3 Endovastec Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Endovastec Peripheral Vasodilator Drugs Product Portfolio
  6. 8.1.5 Endovastec Recent Developments
  7. 8.2 Aotecar Medical-B
  8. 8.2.1 Aotecar Medical-B Company Information
  9. 8.2.2 Aotecar Medical-B Business Overview
  10. 8.2.3 Aotecar Medical-B Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Aotecar Medical-B Peripheral Vasodilator Drugs Product Portfolio
  12. 8.2.5 Aotecar Medical-B Recent Developments
  13. 8.3 Tibet Cheezheng Tibetan Medicine Co., Ltd
  14. 8.3.1 Tibet Cheezheng Tibetan Medicine Co., Ltd Company Information
  15. 8.3.2 Tibet Cheezheng Tibetan Medicine Co., Ltd Business Overview
  16. 8.3.3 Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Product Portfolio
  18. 8.3.5 Tibet Cheezheng Tibetan Medicine Co., Ltd Recent Developments
  19. 8.4 Teva Pharmaceutical Industries Ltd.
  20. 8.4.1 Teva Pharmaceutical Industries Ltd. Company Information
  21. 8.4.2 Teva Pharmaceutical Industries Ltd. Business Overview
  22. 8.4.3 Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio
  24. 8.4.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Peripheral Vasodilator Drugs Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Novartis AG
  32. 8.6.1 Novartis AG Company Information
  33. 8.6.2 Novartis AG Business Overview
  34. 8.6.3 Novartis AG Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis AG Peripheral Vasodilator Drugs Product Portfolio
  36. 8.6.5 Novartis AG Recent Developments
  37. 8.7 Pfizer, Inc.
  38. 8.7.1 Pfizer, Inc. Company Information
  39. 8.7.2 Pfizer, Inc. Business Overview
  40. 8.7.3 Pfizer, Inc. Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer, Inc. Peripheral Vasodilator Drugs Product Portfolio
  42. 8.7.5 Pfizer, Inc. Recent Developments
  43. 8.8 GSK plc
  44. 8.8.1 GSK plc Company Information
  45. 8.8.2 GSK plc Business Overview
  46. 8.8.3 GSK plc Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GSK plc Peripheral Vasodilator Drugs Product Portfolio
  48. 8.8.5 GSK plc Recent Developments
  49. 8.9 Bayer AG
  50. 8.9.1 Bayer AG Company Information
  51. 8.9.2 Bayer AG Business Overview
  52. 8.9.3 Bayer AG Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bayer AG Peripheral Vasodilator Drugs Product Portfolio
  54. 8.9.5 Bayer AG Recent Developments
  55. 8.10 Bat Medical
  56. 8.10.1 Bat Medical Company Information
  57. 8.10.2 Bat Medical Business Overview
  58. 8.10.3 Bat Medical Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bat Medical Peripheral Vasodilator Drugs Product Portfolio
  60. 8.10.5 Bat Medical Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Peripheral Vasodilator Drugs Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 Viatris, Inc.
  68. 8.12.1 Viatris, Inc. Company Information
  69. 8.12.2 Viatris, Inc. Business Overview
  70. 8.12.3 Viatris, Inc. Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Viatris, Inc. Peripheral Vasodilator Drugs Product Portfolio
  72. 8.12.5 Viatris, Inc. Recent Developments
  73. 8.13 Sun Pharmaceutical Industries Ltd.
  74. 8.13.1 Sun Pharmaceutical Industries Ltd. Company Information
  75. 8.13.2 Sun Pharmaceutical Industries Ltd. Business Overview
  76. 8.13.3 Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio
  78. 8.13.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  79. 8.14 Merck & Co., Inc.
  80. 8.14.1 Merck & Co., Inc. Company Information
  81. 8.14.2 Merck & Co., Inc. Business Overview
  82. 8.14.3 Merck & Co., Inc. Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Merck & Co., Inc. Peripheral Vasodilator Drugs Product Portfolio
  84. 8.14.5 Merck & Co., Inc. Recent Developments
  85. 8.15 Lupin
  86. 8.15.1 Lupin Company Information
  87. 8.15.2 Lupin Business Overview
  88. 8.15.3 Lupin Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Lupin Peripheral Vasodilator Drugs Product Portfolio
  90. 8.15.5 Lupin Recent Developments
  91. 8.16 Bristol-Myers Squibb Company
  92. 8.16.1 Bristol-Myers Squibb Company Company Information
  93. 8.16.2 Bristol-Myers Squibb Company Business Overview
  94. 8.16.3 Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Product Portfolio
  96. 8.16.5 Bristol-Myers Squibb Company Recent Developments
  97. 8.17 Boehringer Ingelheim International GmbH
  98. 8.17.1 Boehringer Ingelheim International GmbH Company Information
  99. 8.17.2 Boehringer Ingelheim International GmbH Business Overview
  100. 8.17.3 Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Product Portfolio
  102. 8.17.5 Boehringer Ingelheim International GmbH Recent Developments
  103. 8.18 Abbott Laboratories
  104. 8.18.1 Abbott Laboratories Company Information
  105. 8.18.2 Abbott Laboratories Business Overview
  106. 8.18.3 Abbott Laboratories Peripheral Vasodilator Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Abbott Laboratories Peripheral Vasodilator Drugs Product Portfolio
  108. 8.18.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peripheral Vasodilator Drugs Value Chain Analysis
  2. 9.1.1 Peripheral Vasodilator Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peripheral Vasodilator Drugs Production Mode & Process
  6. 9.2 Peripheral Vasodilator Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peripheral Vasodilator Drugs Distributors
  9. 9.2.3 Peripheral Vasodilator Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst